Consensus $43.12M. The company said, “Teknova is revising its fiscal 2023 outlook for revenue but maintaining its expectation for free cash outflow. The Company now anticipates total revenue of $37 million to $40 million for the fiscal year ending December 31, 2023 (“2023″), which assumes a Lab Essentials range from down 9% to down 5% and a Clinical Solutions range from down 15% to up 5%. The Company continues to anticipate a free cash outflow amount of approximately $30 million for 2023.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on TKNO:
- Teknova Reports Second Quarter 2023 Financial Results
- Alpha Teknova opens GMP-certified facility in California
- Teknova Announces Opening of New GMP-Certified Facility, Increasing Manufacturing Capacity for Custom, High-Quality Life Sciences Reagents
- Teknova to Report Second Quarter 2023 Financial Results on August 10, 2023
- Alpha Teknova, Sartorius BIA Separations share data on AEX platform
